title: Outcomes of patients treated with durable polymer platinum-chromium everolimus-eluting stents: a meta-analysis of randomised trials.
abstract: OBJECTIVE
  The durable polymer platinum-chromium everolimus-eluting stent (PtCr-EES) is a new-generation drug-eluting stent (DES) with a platinum-enriched metallic platform developed to improve the percutaneous treatment of patients with coronary artery disease. We sought to investigate the performance of durable polymer PtCr-EES versus other new-generation DES.
  
  
  RESULTS
  We undertook a meta-analysis of trials in which patients receiving percutaneous coronary intervention (PCI) were randomly assigned to durable polymer PtCr-EES versus other new-generation DES (other DES). Primary efficacy and safety outcomes were target lesion revascularisation (TLR) and definite/probable stent thrombosis (ST), respectively. Secondary outcomes were myocardial infarction (MI), target vessel revascularisation (TVR), death, cardiac death and longitudinal stent deformation (LSD). A total of 11,036 patients in seven trials received a PCI with either durable polymer PtCr-EES (n=6,613) or other DES (n=4,423). This latter group comprised patients treated with biolimus- (n=325), cobalt-chromium everolimus- (n=1,940) or zotarolimus-eluting stents (n=2,158). After a median follow-up of 12 months (interquartile range 12-24), durable polymer PtCr-EES displayed a risk of TLR (odds ratio 0.98, 95% confidence interval [CI]: 0.75-1.29; p=0.90) and definite/probable ST (0.89 [0.55-1.45]; p=0.63) comparable to that of other DES. However, the durable polymer PtCr-EES was associated with a higher risk of LSD (12.05 [1.60-90.71], p=0.02) compared to other DES. There was no significant difference with regard to other secondary outcomes nor was there heterogeneity across trials.
  
  
  CONCLUSIONS
  At one-year follow-up, the durable polymer PtCr-EES displays a performance comparable to that of other new-generation DES platforms.
authors.affiliation: Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cassese
authors.forename: Gjin
authors.initials: G
authors.lastname: Ndrepepa
authors.forename: Robert A
authors.initials: RA
authors.lastname: Byrne
authors.forename: Sebastian
authors.initials: S
authors.lastname: Kufner
authors.forename: Erion
authors.initials: E
authors.lastname: Xhepa
authors.forename: Antoinette
authors.initials: A
authors.lastname: de Waha
authors.forename: Tobias
authors.initials: T
authors.lastname: Rheude
authors.forename: Roisin
authors.initials: R
authors.lastname: Colleran
authors.forename: Daniele
authors.initials: D
authors.lastname: Giacoppo
authors.forename: Yukinori
authors.initials: Y
authors.lastname: Harada
authors.forename: Karl-Ludwig
authors.initials: KL
authors.lastname: Laugwitz
authors.forename: Heribert
authors.initials: H
authors.lastname: Schunkert
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Fusaro
authors.forename: Adnan
authors.initials: A
authors.lastname: Kastrati
mesh_terms: D000368:Aged; D002857:Chromium / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000628:therapy; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy; D062645:Percutaneous Coronary Intervention / Q000379:methods; D010984:Platinum / Q000627:therapeutic use*; D011108:Polymers / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011108:Polymers; D002857:Chromium; D010984:Platinum; D000068338:Everolimus